Glaukos Achieves Pipeline Milestone with Completion of Patient Enrollment in U.S. NDA Phase 3 Clinical Trials for iDose® TR

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the completion of patient enrollment and randomization in its U.S. Food and Drug Administration (FDA) New Drug Application (NDA) Phase 3 clinical trials for the iDose® TR sustained-release travoprost implant. The iDose TR Phase 3 clinical program consi